Author

Weiping Jia

Novartis (Switzerland)Primary ORCID profile (0000-0002-6244-2168 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

Weiping JiaiD1 paper · Shanghai Jiao Tong University

Biology Disciplines

Click to filter author papers

Biochemistry· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:protein folding & dynamics· 1 Assay:protein structure· 1 Assay:structural biology· 1 Organism:virus· 1

Frequent Co-Authors

Ala M. ShaqraiD· 2 shared Celia A. SchifferiD· 2 shared Daniel N. A. BoloniD· 2 shared Dustin DovalaiD· 2 shared Julia M. FlynniD· 2 shared Neşe Kurt YılmaziD· 2 shared Sarah N. ZvornicaniniD· 2 shared Stephanie A. MoquiniD· 2 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBiochemistry

Ala M. ShaqraORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cooperativity and Communication between the Active Sites of the Dimeric SARS-CoV-2 Main Protease

Sarah N. Zvornicanin, Ala M. Shaqra, Julia M. Flynn, Lauren E. Intravaia, Heidi Carias, Weiping Jia, Devendra Kumar Gupta, Stephanie A. Moquin, Dustin Dovala, Daniel N. A. Bolon, Brian A. Kelch, Celia A. Schiffer, Neşe Kurt Yılmaz

This study investigates how the two active sites of SARS-CoV-2 Mpro communicate and cooperate in catalysis using enzymatic assays, crystal structures, and engineered mutations.

Science Advances · Jan 16, 2026Peer-reviewedBiochemistry

Molecular Mechanisms of Drug Resistance and Compensation in SARS-CoV-2 Main Protease: The Interplay Between E166 and L50

Sarah N. Zvornicanin, Ala M. Shaqra, Julia M. Flynn, Heidi Carias Martinez, Weiping Jia, Stephanie A. Moquin, Dustin Dovala, Daniel N. A. Bolon, Neşe Kurt Yılmaz, Celia A. Schiffer

This study investigates drug resistance mechanisms in SARS-CoV-2 Mpro caused by E166 mutations and their compensation by L50F, revealing structural and functional impacts on inhibitor binding and catalytic efficiency.

mBio · Apr 9, 2025Peer-reviewedBiochemistry